Key insights
- Eli Lilly's rapid revenue growth driven by Mounjaro and Zepbound is a major development in the pharma sector. AbbVie's Skyrizi sales indicate that the impact of Humira biosimilars may have been overestimated. Keytruda remains the top-selling drug. This performance could positively influence investor sentiment towards the pharmaceutical sector, particularly companies with strong growth prospects.
Compiled from official Q4 2025 earnings reports. Here is the full picture:
-
Johnson & Johnson: $94.2B
-
Roche: $79.3B
-
Eli Lilly: $65.2B (was $34B in 2023, nearly doubled in 2 years)
-
Pfizer: $62.6B
-
AbbVie: $61.2B
-
AstraZeneca: $58.7B
-
Merck: $58.1B (Keytruda alone: $31.7B)
-
Novartis: $54.5B
-
Sanofi: $51.6B (Dupixent: $18.5B)
-
Novo Nordisk: $49.0B (Ozempic + Wegovy drove this)
- The biggest story here is Eli Lilly adding $30B in revenue in just 2 years purely from 2 drugs. Mounjaro: $23B and Zepbound: $13.5B combined are now bigger than Novo Nordisk's entire annual revenue. * AbbVie's Skyrizi: $17.6B proving the Humira biosimilar threat was overestimated by many analysts. * Keytruda (Merck) remains the world's single best-selling drug at $31.7B
Source: Official company earnings reports